119 related articles for article (PubMed ID: 9925993)
1. A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders.
Naitoh N; Yamaura M; Tagawa M; Aizawa Y
Jpn Heart J; 1998 Sep; 39(5):619-30. PubMed ID: 9925993
[TBL] [Abstract][Full Text] [Related]
2. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
[TBL] [Abstract][Full Text] [Related]
3. Comparative electrophysiologic findings between responders and nonresponders to class III antiarrhythmic drugs among patients with ventricular tachyarrhythmia.
Naitoh N; Washizuka T; Takahashi K; Miyajima T; Aizawa Y
Jpn Heart J; 1998 May; 39(3):307-19. PubMed ID: 9711182
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
5. Frequency-dependent electrophysiologic effects of d,l-sotalol and quinidine and modulation by beta-adrenergic stimulation.
Sager PT; Behboodikhah M
J Cardiovasc Electrophysiol; 1996 Feb; 7(2):102-12. PubMed ID: 8853020
[TBL] [Abstract][Full Text] [Related]
6. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
Kus T; Costi P; Dubuc M; Shenasa M
Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
[TBL] [Abstract][Full Text] [Related]
7. Correlation between the effective refractory period and activation-recovery interval calculated from the intracardiac unipolar electrogram of humans with and without dl-sotalol treatment.
Chinushi M; Tagawa M; Kasai H; Washizuka T; Abe A; Furushima H; Aizawa Y
Jpn Circ J; 2001 Aug; 65(8):702-6. PubMed ID: 11502045
[TBL] [Abstract][Full Text] [Related]
8. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias.
Naitoh N; Tagawa M; Yamaura M; Taneda K; Furushima H; Aizawa Y
Jpn Heart J; 1998 Jul; 39(4):457-67. PubMed ID: 9810296
[TBL] [Abstract][Full Text] [Related]
9. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
Hoffmann E; Mattke S; Haberl R; Steinbeck G
J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
[TBL] [Abstract][Full Text] [Related]
10. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
Singh BN; Kehoe R; Woosley RL; Scheinman M; Quart B
Am Heart J; 1995 Jan; 129(1):87-97. PubMed ID: 7817931
[TBL] [Abstract][Full Text] [Related]
11. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
Sager PT; Follmer C; Uppal P; Pruitt C; Godfrey R
Circulation; 1994 Oct; 90(4):1811-9. PubMed ID: 7923666
[TBL] [Abstract][Full Text] [Related]
12. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Mewis C; Kühlkamp V; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jun; 33(7):1989-95. PubMed ID: 10362204
[TBL] [Abstract][Full Text] [Related]
13. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle.
Huikuri HV; Yli-Mäyry S
Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2103-7. PubMed ID: 1279607
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
[TBL] [Abstract][Full Text] [Related]
15. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Haverkamp W; Martinez-Rubio A; Hief C; Lammers A; Mühlenkamp S; Wichter T; Breithardt G; Borggrefe M
J Am Coll Cardiol; 1997 Aug; 30(2):487-95. PubMed ID: 9247523
[TBL] [Abstract][Full Text] [Related]
19. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
